Ascent Capital Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Ascent Capital Management’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$142K	Buy	+10,184	New	+$147K	0.11%	61

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascent Capital Management's RDY Position: Q3 2025 in Review

Ascent Capital Management opened a new position in Dr. Reddy's Laboratories (RDY) in Q3 2025: 10,184 shares worth $142K. The stake represents 0.11% of the portfolio and ranks #61 among its holdings.

227 funds tracked by Wall St. Rank hold RDY as of Q3 2025.

Ascent Capital Management held 10,184 shares of Dr. Reddy's Laboratories worth $142K as of Q3 2025.
Dr. Reddy's Laboratories was a new Ascent Capital Management position in Q3 2025.
Dr. Reddy's Laboratories made up 0.11% of Ascent Capital Management's portfolio in Q3 2025, its #61 holding.
227 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2025.

Based on Ascent Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.